{ "version": "2026-08-30.1", "snapshot_date": "2026-08-30", "owner": "https://stemcellatlas.com/en/data/longevity-comparisons", "method": "Figures reproduce selected, source-linked tables already reviewed by StemCellAtlas. The GLP-1 table selects name, form and status from the reviewed comparison tool. No source records were altered and no new clinical results were added.", "reuse": "You may reuse these StemCellAtlas-created figures and captions with source attribution. This permission does not cover the underlying papers, registry records or third-party works. Keep the snapshot date and scope note when quoting a figure.", "figures": [ { "id": "glp-1-products", "title": "GLP-1 products and trial candidates", "note": "Six selected formulations and candidates, not the complete GLP-1 pipeline. US label information and sponsor trial reports are different source types. This is not an efficacy comparison or prescribing guide.", "widths": [ 380, 290, 410 ], "headers": [ "Product / molecule", "Form in the source", "US label or trial status" ], "rows": [ [ "Wegovy injection · semaglutide", "Weekly injection", "US-labelled formulation" ], [ "Wegovy pill · semaglutide", "Daily tablet", "US-labelled formulation" ], [ "Zepbound · tirzepatide", "Weekly injection", "US-labelled formulation" ], [ "Foundayo · orforglipron", "Daily pill", "FDA approval: 1 April 2026" ], [ "Retatrutide", "Weekly injection in trials", "Investigational; not an FDA-approved drug" ], [ "CagriSema", "Weekly injection in trials", "Phase 3 sponsor report; not a product label" ] ], "page": "https://stemcellatlas.com/en/quiz/new-glp-1-comparison", "snapshot_date": "2026-08-30", "sources": [ "https://investor.lilly.com/node/54321/pdf", "https://pi.lilly.com/us/zepbound-uspi.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program", "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501" ], "sources_by_row": [ [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf" ], [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf" ], [ "https://pi.lilly.com/us/zepbound-uspi.pdf" ], [ "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program" ], [ "https://investor.lilly.com/node/54321/pdf", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ], [ "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501" ] ], "registry_records": [], "export": "/data/growth/glp-1-products", "figure_width": 1200, "figure_height": 1126, "figure_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-products.svg", "png_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-products.png", "caption_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-products.txt", "svg_sha256": "5fe49bc424ab848bd3bd63ae74bbc2c631bb136debffe38fbaf95355b21e0a2e", "png_sha256": "068a598ac4f17705964c45f03e672e0c776507e8a941e3790841b6dec079e7e4" }, { "id": "peptide-stack-names", "title": "Wolverine, GLOW and KLOW: reported ingredients", "note": "Names as defined by KLOW Clinic; sellers may use different formulations. Ingredient lists do not establish the effectiveness or safety of a combination.", "widths": [ 290, 790 ], "headers": [ "Reported name", "Listed ingredients" ], "rows": [ [ "Wolverine", "BPC-157 + TB-500" ], [ "GLOW", "BPC-157 + TB-500 + GHK-Cu" ], [ "KLOW", "BPC-157 + TB-500 + GHK-Cu + KPV" ] ], "page": "https://stemcellatlas.com/en/compare/glow-vs-klow-peptide-stack", "snapshot_date": "2026-08-30", "sources": [ "https://klowclinic.com/faq" ], "registry_records": [], "export": "/data/growth/glow-vs-klow-peptide-stack", "figure_width": 1200, "figure_height": 724, "figure_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/peptide-stack-names.svg", "png_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/peptide-stack-names.png", "caption_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/peptide-stack-names.txt", "svg_sha256": "9b21150c02e2cf34144539bcaf50691284dd7b18888f27b0f9ba5b37701c178d", "png_sha256": "b92c96dbbccaf1bff71ee738ff4cb85fdb02010770c8bcfd57281cb294882977" }, { "id": "biological-age-methods", "title": "Biological-age methods: inputs and outputs", "note": "Four selected methods, not a ranking. An age estimate and a pace-of-aging measure are different outputs; these rows are not interchangeable test results.", "widths": [ 290, 350, 440 ], "headers": [ "Method", "Inputs", "What the model estimates" ], "rows": [ [ "Clinical Phenotypic Age", "Nine clinical biomarkers plus chronological age", "A mortality-risk-based age estimate, in years" ], [ "DNAm PhenoAge", "DNA methylation at 513 sites", "A methylation estimate of Phenotypic Age" ], [ "Original Horvath clock", "DNA methylation at 353 sites", "Age from a model trained on chronological age" ], [ "DunedinPACE", "Blood DNA methylation at 173 sites", "Pace of aging, not age in years" ] ], "page": "https://stemcellatlas.com/en/compare/biological-age-tests-compared", "snapshot_date": "2026-08-30", "sources": [ "https://pmc.ncbi.nlm.nih.gov/articles/PMC4015143/", "https://pmc.ncbi.nlm.nih.gov/articles/PMC5940111/", "https://pmc.ncbi.nlm.nih.gov/articles/PMC8853656/" ], "registry_records": [], "export": "/data/growth/biological-age-tests-compared", "figure_width": 1200, "figure_height": 966, "figure_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/biological-age-methods.svg", "png_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/biological-age-methods.png", "caption_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/biological-age-methods.txt", "svg_sha256": "3d532087c6b3db53493c02b42a9d1d398b9ba78ba40547a1296eadc3f3879ce5", "png_sha256": "2d0616551dd5d11600392e8c07c37dd26a32ef003af026b36ce1fdb85e4a5f7d" }, { "id": "glp-1-creatine-trial", "title": "Creatine during GLP-1 treatment: trial design", "note": "NCT07625202: a registered trial design, not a treatment result. The estimated enrolment is not the number of participants who completed the trial.", "widths": [ 320, 760 ], "headers": [ "Field", "Retrieved record" ], "rows": [ [ "Participants", "40 estimated" ], [ "Status", "Recruiting" ], [ "Comparison", "Creatine vs placebo; resistance training" ], [ "Primary outcome", "Sit-to-stand performance, 12 weeks" ], [ "Lean tissue", "Secondary DXA outcome, 12 weeks" ], [ "Posted results", "None in the retrieved record" ] ], "page": "https://stemcellatlas.com/en/guides/glp-1-creatine", "snapshot_date": "2026-08-30", "sources": [ "https://clinicaltrials.gov/study/NCT07625202" ], "registry_records": [ { "registry": "ClinicalTrials.gov", "nct_id": "NCT07625202", "registry_last_update_posted": "2026-06-04", "retrieved_on": "2026-08-30", "modifications": "Selected fields, shortened labels and editorial comparison; original registry record unchanged." } ], "export": "/data/growth/glp-1-creatine", "figure_width": 1200, "figure_height": 1056, "figure_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-creatine-trial.svg", "png_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-creatine-trial.png", "caption_url": "https://stemcellatlas.com/data/figures/2026-08-30.1/glp-1-creatine-trial.txt", "svg_sha256": "76419c57d003b98771c163d1259d3d7fb1895125c3d3abb36429effb4a6848e9", "png_sha256": "b61033d3b5a3d933b6d7762daf42ef7d9f341130705798d623cf7541a9f31a76" } ] }